Relación entre los anticuerpos contra antígenos extraíbles del núcleo y las enfermedades del tejido conectivo identificados por Immunoblots en un hospital y universidad de Lima

  • José Enrique Oliva Menacho Hospital Nacional Arzobispo Loayza, Lima, Perú
  • Jorge Luis Arroyo Acevedo Universidad Nacional Mayor de San Marcos, Lima, Perú
  • Jose Arturo Oliva Candela Hospital Nacional Arzobispo Loayza, Lima, Perú
  • Percy Genaro Salas Ponce Hospital Nacional Arzobispo Loayza, Lima, Perú
  • Marco Antonio Garcia Hjarles Hospital Nacional Arzobispo Loayza, Lima, Perú
Palabras clave: anticuerpos contra antígenos del núcleo extraíbles, Immunoblots, enfermedades autoinmunes, Perú. (Fuente: MeSH NLM)

Resumen

Objetivos: determinar la relación de los anticuerpos con los antígenos del núcleo extraíble y las enfermedades del tejido conectivo identificadas por Immunoblot en un hospital de Lima, Perú. Material y métodos: estudio de tipo observacional, ciencias básicas, analíticas y transversales, realizado en el Servicio de Inmunología del Hospital Nacional Arzobispo Loayza entre enero de 2018 y junio de 2018. Analizamos 291 historias clínicas de pacientes con enferme-dad del tejido conectivo y para la detección de anticuerpos contra los antígenos extraíbles del núcleo se empleó el método de Immunoblots.

Biografía del autor/a

Marco Antonio Garcia Hjarles, Hospital Nacional Arzobispo Loayza, Lima, Perú
Facultad de Ciencias y Filosofía

Citas

I. Kumar S, Aggarwa A. Approach to a patient with connective tissue disease. The Indian Journal of Pediatrics. 2010;77(10): 1157-1164.

II. Abumohor P. Enfermedades del tejido conectivo: importancia del diagnóstico precoz. Revista Médica de Clínica Las Condes. 2012; 23(4): 391-400.

III. Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y. Clinical and patholo-gical roles of Ro/SSA autoantibody system. Clinical and Develop-mental Immunology. 2012; 2012(1):1-12.

IV. Xue D, Shi H, Smith JD, Chen X, Noe DA, Cedervall T, et al. A lu-pus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proceedings of the National Academy of Sciences. 2003;100(13):7503-8.

V. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and an-ti-RNP antibodies. Autoimmunity. 2005;38(1):47-54.

VI. Agarwal S, Harper J, Kiely PDW. Concentration of antibodies to ex-tractable nuclear antigens and disease activity in systemic lupus erythematosus. Lupus. 2009;18(5):407-12.

VII. Kurien BT, Scofield RH. Autoantibody Determination in the Diag-nosis of Systemic Lupus Erythematosus. Scandinavian Journal of Immunology. 2006;64(3):227-35.

VIII. Kvarnstrom M, Dzikaite-Ottosson V, Ottosson L, Gustafsson JT, Gunnarsson I, Svenungsson E et al. Autoantibodies to the functio-nally active RING-domain of Ro52/SSA are associated with disease activity in patients with lupus. Lupus. 2013;22(5):477-85.

IX. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheumatology. 1982;25(11):1271-7.

X. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Co-llaborating Clinics classification criteria for systemic lupus erythe-matosus. Arthritis Rheumatology. 2012;64(8):2677-86.

XI. Egner W. The use of laboratory tests in the diagnosis of SLE. Journal of Clinical Pathology. 2000;53(6):424-432.

XII. Martinez-Cordero E, Martinez-Miranda E, Negrete-Garcia MC, Padi-lla A, Aguilar Leon DE. Anti-dsDNA and Sm autoantibodies in sys-temic lupus erythematosus. Clinical Rheumatology. 1992;11(3):341-345.

XIII. Agarwal S, Harper J, Kiely P. Concentration of antibodies to ex-tractable nuclear antigens and disease activity in systemic lupus erythematosus. Lupus. 2009;18(5):407-12.

XIV. 14. Gussin H, Ignat G, Varga J, Teodorescu M. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythema-tosus. Arthritis Rheumatology. 2001;44(2):376-383.

XV. Albon S, Bunn C, Swana G. Performance of a multiplex assay com-pared to enzyme and precipitation methods for anti-ENA testing in systemic lupus and systemic sclerosis. Journal of Immunologi-cal Methods. 2011;365(1-2): 126-131.

XVI. Ghedira, I., Landolsi, H., & Mankai, A. Antihistones antibodies in systemic lupus erythematosus, comparison of three assays: elisa, dot blot and immunoblot. Pathologie Biologie. 2006; 54(3): 148-154.

XVII. Albon S, Bunn C, Swana G. Performance of a multiplex assay com-pared to enzyme and precipitation methods for anti-ENA testing in systemic lupus and systemic sclerosis. Journal of Immunologi-cal Methods. 2011; 365(1-2):126-131.

XVIII. Schulte J, Fritzler M, Mahler M. Latest update on the Ro/SS-A au-toantibody system. Autoimmunity Reviews. 2009; 8(7): 632-637.

XIX. Catoggio L, Bernstein R, Black C. Serological markers in progressive systemic sclerosis: clinical correlations. Annals of the Rheumatic Diseases.1983.42(1): 23-27.

XX. Shinjo S, Levy-Neto M. Anti-Jo-1 antisynthetase syndrome. Revista Brasileira de Reumatología. 2010. 50(5): 492-500.

XXI. Tozzoli R, Bizzarro N, Tonutti E, Villalta D, Bassetti D, Manoni F, et al. Guidelines for the laboratory use of autoantibody test in the diag-nosis and monitoring of autoimmune rheumatic diseases. Ameri-can Journal of Clinical Pathology. 2002;117(2):316-24.

XXII. Severiche D, Escobar M, Naranjo L, García A, Vahos C, Duque G. Ciento quince pacientes con lupus eritematoso sistémico: Carac-terísticas clínicas e inmunológicas. Revista Colombiana de Reuma-tologia.2004;21(4):183-92.

XXIII. Aggarwal A. Role of autoantibody testing. Best Practice & Research Clinical Rheumatology. 2014; 28(6): 907–20.

XXIV. Mierendorf S, Shmerling RH. Antinuclear antibody testing. Hosp Med Clin. 2012;1: 370–7.

XXV. Manoussakis M, Kistis K, Liu X, Aidinis V, Guialis A, Moutsopoulos H. Detection of anti-Ro (SSA) antibodies in autoimmune diseases: comparison of five methods. British J Rheumatol.1993; 32(6): 449-455.

XXVI. Reichlin M and Scofield RH. SSA(Ro) autoantibodies. En: James B. Peter and Yehuda Shoenfeld eds. Autoantibodies. Elsevier, 1996.

XXVII. Tzioufas A, Moutsopoulos H. Clinical significance of autoantibo-dies to Ro/SSA and La/SSB. En: van Venrooij WJ and Maini RN eds. Manual of Biological Markers of Diseases. Kluwer Academic Publi-shers, 1996.

XXVIII. Wahren M, Téngner P, Gunnarsson I, Lundberg I, Hedfors E, Rin-gertz NR, Pettersson I. Ro/SS-A and La/SS-B antibody level va-riation in patients with Sjogren’s syndrome and systemic lupus erythematosus. J Autoimmun 1998;11(1):29-38.

XXIX. Boire G, Gendron M, Monast N, Bastin B, Menard H. Purification of antigenically intact Ro ribonucleoproteins; biochemical and im-munological evidence that the 52-kD protein is not a Ro protein. Clinical and experimental Immunology.1995;100(3):489-498.

XXX. Le Roy EC, Black C, Fleischmajer R. Scleroderma (systemic sclero-sis): Classification subsets and pathogenesis. J. Rheumatol. 1980; 15(2):202-205.

XXXI. Hanke K, Uibel S, Bruckner C, Dahnrich C, Egerer K, Hiepe F, Schu-lumberger W, Riemekasten G. An-tibodies to CENP – B antigen identify a subgroup of systemic sclerosis patients presenting more frequently sicca syndrome and less frequently lung fibrosis, car-diac and vascular involvement- analysis of the Charite SSc cohort. En: Conrad K et al. (Hrsg.). From Etiopathogenesis to the predic-tion of autoimmune diseases: Relevance of Autoantibodies. Pabst Science Publisher ;5(2007): 477-478.

Publicado
2020-06-01
Cómo citar
1.
Oliva Menacho JE, Arroyo Acevedo JL, Oliva Candela JA, Salas Ponce PG, Garcia Hjarles MA. Relación entre los anticuerpos contra antígenos extraíbles del núcleo y las enfermedades del tejido conectivo identificados por Immunoblots en un hospital y universidad de Lima. Rev. Argent. Reumatol. [Internet]. 1 de junio de 2020 [citado 30 de enero de 2023];31(2):25 -30. Disponible en: https://ojs.reumatologia.org.ar/index.php/revistaSAR/article/view/405
Sección
Artículo Original